- Home
- GGZ vs RPTX Comparison
GGZ vs RPTX Comparison
Compare GGZ & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.60
Company Overview
Basic Information| Metric | GGZ | RPTX |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 92.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GGZ | RPTX |
|---|---|---|
| Price | $15.33 | $2.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 12.8K | ★ 1.7M |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | N/A | ★ $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,122.22 |
| P/E Ratio | $6.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.43 | $0.89 |
| 52 Week High | $12.50 | $2.66 |
Technical Indicators
Market Signals| Indicator | GGZ | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 77.84 | 68.79 |
| Support Level | $15.33 | $2.50 |
| Resistance Level | $15.70 | $2.61 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 100.00 | 76.00 |
Price Performance
Historical Comparison GGZ
RPTX
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.